{"id":6801,"date":"2023-05-04T06:00:00","date_gmt":"2023-05-04T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/"},"modified":"2023-05-04T06:00:00","modified_gmt":"2023-05-04T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-mars-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Positiva prekliniska data med NEX-22, NEX-20 fas I fortg\u00e5r och bra framdrift i partnerprojekten<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet 2023<\/p>\n<ul>\n<li>Nanexa AB meddelade lyckat utfall i den f\u00f6rsta prekliniska studien med NEX-22. I en enm\u00e5nadsstudie p\u00e5 r\u00e5ttor har singeldoser av tv\u00e5 olika PharmaShell\u00ae-formuleringar studerats i olika doser. Resultaten visar en kontrollerad fris\u00e4ttning av liraglutid, med plasmaexponering \u00f6ver 28 dagar f\u00f6r NEX-22 j\u00e4mf\u00f6rt med cirka 2 dagar f\u00f6r en l\u00f6sning av liraglutid utan PharmaShell.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Inga v\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng.<\/li>\n<\/ul>\n<p>Sammanfattning av rapportperioden 1 januari-31 mars 2023<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 8 173 (298) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -8 703 (-12 331) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -8 603 (-12 370) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,14 (-0,24) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -20 682 (-17 934) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 60 500 (87 726) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida via f\u00f6ljande l\u00e4nk, <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Rapportkommentar 4 maj kl 15:00<\/strong><br \/>En lives\u00e4nd kommentar med CFO Bj\u00f6rn Svanstr\u00f6m h\u00e5lls den 4 maj kl. 15:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=h-A-YNrq85E\" rel=\"noopener\" target=\"_blank\">Rapportkommentaren kommer att finnas tillg\u00e4nglig visa denna l\u00e4nk<\/a>.<br \/>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2023-05-04 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/f9cc5193-8cd4-4cdc-9ccd-0e873ab24dea\/nanexa-delarsrapport-jan-mar-2023.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Jan Mar 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Positiva prekliniska data med NEX-22, NEX-20 fas I fortg\u00e5r och bra framdrift i partnerprojekten<\/p>\n","protected":false},"template":"","class_list":["post-6801","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn-cus-disclaimer_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q1_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Positiva prekliniska data med NEX-22, NEX-20 fas I fortg\u00e5r och bra framdrift i partnerprojekten\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-05-04T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB","og_description":"Positiva prekliniska data med NEX-22, NEX-20 fas I fortg\u00e5r och bra framdrift i partnerprojekten","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-05-04T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}